Comparative Pharmacology
Head-to-head clinical analysis: MYHIBBIN versus NATACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYHIBBIN versus NATACYN.
MYHIBBIN vs NATACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
Natamycin is a polyene antifungal that binds to ergosterol in fungal cell membranes, increasing permeability and causing cell death.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
One drop of 5% ophthalmic suspension into the conjunctival sac every 1-2 hours for 48 hours, then taper to one drop 4-6 times daily.
None Documented
None Documented
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Not well characterized due to minimal systemic absorption; estimated to be 2-3 hours in plasma if absorbed.
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Primarily fecal via biliary elimination; less than 5% renal excretion of absorbed dose.
Category C
Category C
Antifungal
Antifungal, Ophthalmic